Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.

abstract：:Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic and pharmacokinetic/pharmacodynamic relationships were evaluated. Using nonlinear mixed effects modelin...

journal_title：Journal of clinical pharmacology

authors： Rini BI,Garrett M,Poland B,Dutcher JP,Rixe O,Wilding G,Stadler WM,Pithavala YK,Kim S,Tarazi J,Motzer RJ

更新日期：2013-05-01 00:00:00

abstract：:The short-term effect of the blockade of the beta-adrenergic receptors on serum lipoproteins and the plasma activities of the enzymes involved in the metabolism of the serum lipoproteins: lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin: cholesterol acyltransferase (LCAT) was evaluated in ten healthy normoli...

journal_title：Journal of clinical pharmacology

authors： Harvengt C,Heller FR,Martiat P,Van Nieuwenhuyze Y

更新日期：1987-07-01 00:00:00

abstract：:To determine whether adefovir (ADV) in combination with entecavir (ETV) is more effective than with lamivudine (LAM) in patients with lamivudine-resistant chronic HBV infection, electronic databases were searched through May 10th, 2013 to obtain relevant trials which met the inclusion criteria. Meta-analysis was perfo...

journal_title：Journal of clinical pharmacology

authors： Zeng T,Xu H,Liu JY,Lei Y,Zhong S,Zhou Z

更新日期：2014-09-01 00:00:00

abstract：:Two populations of critical care patients were studied using indices of renal tubular damage (beta 2-microglobulin, enzymes, casts) and indices of glomerular filtration (creatinine, creatinine clearance). The purpose of these studies had been initially to elucidate the type of renal failure typical of the critically i...

journal_title：Journal of clinical pharmacology

authors： Schentag JJ

更新日期：1983-10-01 00:00:00

abstract：:Consumption of typical quantities of grapefruit juice (GFJ) increases the oral bioavailability of several CYP3A4 substrates without affecting their elimination, consistent with selective inhibition of intestinal but not hepatic CYP3A4. However, increases in the AUCs of CYP3A4 substrates recently associated with the co...

journal_title：Journal of clinical pharmacology

authors： Veronese ML,Gillen LP,Burke JP,Dorval EP,Hauck WW,Pequignot E,Waldman SA,Greenberg HE

更新日期：2003-08-01 00:00:00

abstract：:Concentrations in breast milk of medications used during general anesthesia were measured to determine whether interruption of breast-feeding was indicated. Breast milk and maternal blood samples were obtained from nine women undergoing tubal sterilization under general anesthesia. Concentrations of methohexital, mepe...

journal_title：Journal of clinical pharmacology

authors： Borgatta L,Jenny RW,Gruss L,Ong C,Barad D

更新日期：1997-03-01 00:00:00

abstract：:This 30-center, randomized, double-blind, placebo-controlled, parallel-group study was designed to (1) establish that 6.25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effectiveness in patients with stage I and stage II (mild to moderate) systemi...

journal_title：Journal of clinical pharmacology

authors： Frishman WH,Burris JF,Mroczek WJ,Weir MR,Alemayehu D,Simon JS,Chen SY,Bryzinski BS

更新日期：1995-02-01 00:00:00

abstract：:The selective T-cell costimulation modulator abatacept is approved for treatment of adult rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA; 6-17 years [intravenous] and 2-17 years [subcutaneous]). An extrapolation approach was taken to determine subcutaneous weight-tiered doses of abatac...

journal_title：Journal of clinical pharmacology

authors： Gandhi Y,Passarell JA,Roy A,Murthy B

更新日期：2020-12-07 00:00:00

abstract：:The present study was conducted to determine the absolute bioavailability of fimasartan (FMS; Kanarb(®) ) after the single oral administration of a 60-mg tablet or a single 30-mg intravenous (IV) infusion. This investigation was a randomized, single-dose, open-labeled, two-way crossover study of 16 healthy Korean male...

journal_title：Journal of clinical pharmacology

authors： Ghim JL,Paik SH,Hasanuzzaman M,Chi YH,Choi HK,Kim DH,Shin JG

更新日期：2016-05-01 00:00:00

abstract：:The hypotensive effect, kinetics, and concentration-response relationship of labetalol, alpha beta- and alpha 1-adrenoceptor blocking drug, were studied in seven women with a moderate-to-severe hypertension (averaged diastolic blood pressure [DBP] of 100 to 120 mm Hg measured during a 1- to 2-day hospitalization perio...

journal_title：Journal of clinical pharmacology

authors： Saotome T,Minoura S,Terashi K,Sato T,Echizen H,Ishizaki T

更新日期：1993-10-01 00:00:00

abstract：:Relationships between tocilizumab exposure and response were evaluated using data from 4 phase III studies. Increased tocilizumab exposure was associated with improvements in Disease Activity Score using 28 joints (DAS28) and American College of Rheumatology (ACR) criteria and with a decrease in inflammation markers. ...

journal_title：Journal of clinical pharmacology

authors： Levi M,Grange S,Frey N

更新日期：2013-02-01 00:00:00

abstract：:Vitamin B6 has been known to possess antiemetic effects since 1942. This water soluble compound has several forms in the circulation including pyridoxine, pyridoxal, and pyridoxal phosphate. The active antiemetic form of vitamin B6 is unknown. This was a pre-specified substudy of a randomized, placebo-controlled trial...

journal_title：Journal of clinical pharmacology

authors： Matok I,Clark S,Caritis S,Miodovnik M,Umans JG,Hankins G,Mattison DR,Koren G

更新日期：2014-12-01 00:00:00

abstract：:The isoproterenol sensitivity (dose-response curve) and the total body clearance of propranolol were measured in 80 men including 15 normal subjects and 65 essential hypertensive patients (20 borderline and 45 permanent hypertensives). The critical dose of isoproterenol was found to be directly correlated to weight (P...

journal_title：Journal of clinical pharmacology

authors： London GM,Safar ME,Weiss YA,Milliez PL

更新日期：1976-04-01 00:00:00

abstract：:The aim of the study was to investigate the pharmacokinetics and removal of midazolam and unconjugated and glucuronidated 1-hydroxy-midazolam in 4 intensive care patients on continuous venovenous hemodialysis. Plasma midazolam and its metabolites were assessed by HPLC from blood samples collected during continuous inf...

journal_title：Journal of clinical pharmacology

authors： Bolon M,Bastien O,Flamens C,Paulus S,Boulieu R

更新日期：2001-09-01 00:00:00

abstract：:This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel depot formulation of abarelix, a new gonadotropin-releasing hormone (GnRH) antagonist. This was an open-label, sequential two-phase study in healthy male subjects ages 50 to 75. Subjects received a single intramuscular (IM) do...

journal_title：Journal of clinical pharmacology

authors： Wong SL,Lau DT,Baughman SA,Fotheringham N,Menchaca D,Garnick MB

更新日期：2004-05-01 00:00:00

abstract：:Twelve patients chronically maintained on warfarin were administered 80 mg atorvastatin for 2 weeks. Mean prothrombin times decreased slightly, but only for the first few days of the two-week treatment period. Thus atorvastatin had no consistent effect on the anticoagulant activity of warfarin and adjustment in warfar...

journal_title：Journal of clinical pharmacology

authors： Stern R,Abel R,Gibson GL,Besserer J

更新日期：1997-11-01 00:00:00

abstract：:In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2-receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan was initiated as daily morning/afternoon doses of 45/15 mg, and uptitrated weekly to 60/30 mg and 90/30 mg according to pa...

journal_title：Journal of clinical pharmacology

authors： Shoaf SE,Chapman AB,Torres VE,Ouyang J,Czerwiec FS

更新日期：2017-07-01 00:00:00

abstract：:The pharmacokinetics, pharmacodynamics, and safety of fosinopril sodium (SQ 28,555), a new orally active angiotensin-converting enzyme (ACE) inhibitor, was evaluated in 73 healthy men in two separate studies. In study I, doses ranging from 10 to 640 mg were administered once daily for 3 days to seven groups of five su...

journal_title：Journal of clinical pharmacology

authors： Duchin KL,Waclawski AP,Tu JI,Manning J,Frantz M,Willard DA

更新日期：1991-01-01 00:00:00

abstract：:CGS 13080, a selective thromboxane synthetase inhibitor, was given intravenously (0.6 mg/kg over 6 hours) to eight hypertensive (diastolic 95-115 mm Hg) euvolemic caucasian females on their customary salt intake (24 hour urine Na: 142.9 +/- 14.8 meq). No change occurred in blood pressure or glomerular filtration rate ...

journal_title：Journal of clinical pharmacology

authors： Weir MR,Klassen DK,Hoover N,Douglas FL

更新日期：1989-12-01 00:00:00

abstract：:Bococizumab (RN316/PF-04950615), a humanized monoclonal antibody, binds to secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevents its downregulation of low-density lipoprotein receptor, leading to improved clearance and reduction of low-density lipoprotein cholesterol (LDL-C) in plasma. A mechanis...

journal_title：Journal of clinical pharmacology

authors： Udata C,Garzone PD,Gumbiner B,Joh T,Liang H,Liao KH,Williams JH,Meng X

更新日期：2017-07-01 00:00:00

abstract：:The authors examined the pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in 17 patients (4 children, 13 adults) with B-lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL) and 5 patients with non-Hodgkin's lymphoma (NHL). The immunoconjugat...

journal_title：Journal of clinical pharmacology

authors： Chen CL,Levine A,Rao A,O'Neill K,Messinger Y,Myers DE,Goldman F,Hurvitz C,Casper JT,Uckun FM

更新日期：1999-12-01 00:00:00

abstract：:This was a double-blind, placebo-controlled, randomized, parallel, dose-escalation study to assess the pharmacokinetics, platelet response, safety, and tolerability of supratherapeutic doses of eltrombopag (100 mg, 150 mg, and 200 mg once daily) administered for 5 days to 33 healthy adult volunteers. Plasma eltrombopa...

journal_title：Journal of clinical pharmacology

authors： Matthys G,Park JW,McGuire S,Wire MB,Bowen C,Williams D,Jenkins J,Peng B

更新日期：2011-03-01 00:00:00

abstract：:DS-1040, a low-molecular-weight imidazole derivative, inhibits the enzymatic activity of thrombin-activatable fibrinolysis inhibitor (TAFIa), enhancing endogenous tissue plasminogen activator-triggered fibrinolysis. This first-in-human, randomized, placebo-controlled, phase 1 study evaluated the safety, pharmacokineti...

journal_title：Journal of clinical pharmacology

authors： Zhou J,Limsakun T,Yin O,Warren V,Zamora C,Atiee G,Kochan J,Pav J,Kobayashi F,Vashi V,Dishy V

更新日期：2019-12-01 00:00:00

abstract：:Heparin-induced thrombocytopenia (HIT) is a high-risk adverse drug reaction because of its associated risk of life- and limb-threatening thrombosis. Rivaroxaban may be considered as an ideal nonheparin anticoagulant alternative for the management of HIT. In this preliminary retrospective study, the efficacy and safety...

journal_title：Journal of clinical pharmacology

authors： Farasatinasab M,Zarei B,Moghtadaei M,Nasiripour S,Ansarinejad N,Zarei M

更新日期：2020-10-01 00:00:00

abstract：:ABT-761 is a second-generation 5-lipoxygenase inhibitor in clinical development for the treatment of asthma. The effects of ABT-761 on the pharmacokinetics of an oral contraceptive were assessed in 21 female adult volunteers in a phase I, multiple-dose, open-label study. Subjects received a single dose of oral contrac...

journal_title：Journal of clinical pharmacology

authors： Wong SL,O'Dea RF,Dube LM,Awni WM

更新日期：1998-07-01 00:00:00

abstract：:The cytochromes P450 (CYPs) constitute a superfamily of hemoprotein enzymes that are responsible for the biotransformation of numerous xenobiotics, including therapeutic agents. Studies of the biochemical and enzymatic properties of these enzymes and their molecular genetics and regulation of gene expression and activ...

journal_title：Journal of clinical pharmacology

authors： Venkatakrishnan K,Von Moltke LL,Greenblatt DJ

更新日期：2001-11-01 00:00:00

abstract：:Universally present but overlooked cavities or pockets in long-lived biopharmaceuticals, such as monoclonal antibodies (mAbs), are capable of binding small drugs. Such direct interactions can alter the pharmacokinetics of drugs and potentially affect clinical outcome. The extreme differences in the pharmacokinetic pro...

journal_title：Journal of clinical pharmacology

authors： Panayotatos N

更新日期：2008-10-01 00:00:00

abstract：:This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituximab concentration data were well described by a 2-compartment model c...

journal_title：Journal of clinical pharmacology

authors： Li J,Zhi J,Wenger M,Valente N,Dmoszynska A,Robak T,Mangat R,Joshi A,Visich J

更新日期：2012-12-01 00:00:00

abstract：:Quinapril, a nonsulfhydryl ACE inhibitor, was evaluated in ten New York Heart Association (NYHA) functional class (FC) II-III CHF patients to determine its effects on regional blood flow [effective renal plasma flow (ERPF), renal blood flow (RBF), renal vascular resistance (RVR), hepatic blood flow (HBF), hepatic vasc...

journal_title：Journal of clinical pharmacology

authors： Munger MA,Chance M,Nair R,Prescott AW,Nara AR,Simonson MS,Green JA,Posvar EL

更新日期：1992-01-01 00:00:00

abstract：:The electrocardiographic (ECG) effects of rivastigmine treatment were assessed in mild to moderately severe Alzheimer's disease (AD) by analysis of four 26-week, double-blind, multicenter, placebo-controlled, phase III clinical trials. Of an initial 2791 patients, 77% completed treatment. Seventy-one percent required ...

journal_title：Journal of clinical pharmacology

authors： Morganroth J,Graham S,Hartman R,Anand R

更新日期：2002-05-01 00:00:00